甲胺和心房动:对它们的关联进行系统审查
Mohammad Burhanuddin1, Vaishnavi Jamched2, Muhammad Haris3
1Medicine, Bhaskar Medical College, Hyderabad, IND.
Cureus
|August 14, 2024
概括
一种糖尿病药物梅特福明在预防2型糖尿病患者心房动 (AF) 方面显示出混合的结果. 一些研究表明AF风险降低,特别是长时间使用,但需要更多的研究.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 心房动 (AF) 是一种普遍的心律失常,随着年龄的增长而增加,并与2型糖尿病 (T2DM) 相关.
- 甲福明是一种一线T2DM治疗方法,具有抗炎和抗氧化特性,表明潜在的心血管益处.
- 甲福尔明在减轻AF风险中的作用值得研究,因为其广泛使用和类效应.
研究的目的:
- 系统地审查现有研究,研究二型糖尿病患者的甲福明使用与心房动风险之间的关联.
- 综合关于甲福明对AF发病率的潜在保护性或有害影响的研究结果.
- 发现当前研究中的差距,并为未来的研究提出方向.
主要方法:
- 五项研究的系统综述 (1个动态队列,3个回顾性队列,1个案例报告).
- 在包括PubMed,Embase和Cochrane图书馆在内的主要数据库中进行文献搜索.
- 对研究设计,患者种群和关于甲福明和AF的报告结果的分析.
主要成果:
- 结果是异质的:一些研究表明,甲福林使用与减少AF发病率有关,而另一些研究显示没有显著的关联.
- 在一项大型队列研究中观察到剂量-反应关系,将长期使用甲福林与降低AF风险联系起来.
- 一份病例报告强调了甲福尔诱导的乳酸作为AF发作的潜在触发因素,表明了可能的不良影响.
结论:
- 目前关于甲福明在AF预防中的作用的证据是不确定的,原因是混合的结果和研究异质性.
- 需要进一步进行强有力的研究,特别是前性研究,以确定因果关系和阐明机制.
- 研究甲福明对心房重塑和电生理学的性作用对于了解其在AF预防中的潜力至关重要.
相关概念视频
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
800
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
800
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405